Cargando…
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450327/ https://www.ncbi.nlm.nih.gov/pubmed/25860291 http://dx.doi.org/10.1038/bcj.2015.27 |
| _version_ | 1782373992775024640 |
|---|---|
| author | Dwojak, M Bobrowicz, M Bil, J Bojarczuk, K Pyrzynska, B Siernicka, M Malenda, A Lech-Maranda, E Tomczak, W Giannopoulos, K Golab, J Winiarska, M |
| author_facet | Dwojak, M Bobrowicz, M Bil, J Bojarczuk, K Pyrzynska, B Siernicka, M Malenda, A Lech-Maranda, E Tomczak, W Giannopoulos, K Golab, J Winiarska, M |
| author_sort | Dwojak, M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4450327 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-44503272015-06-09 Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins Dwojak, M Bobrowicz, M Bil, J Bojarczuk, K Pyrzynska, B Siernicka, M Malenda, A Lech-Maranda, E Tomczak, W Giannopoulos, K Golab, J Winiarska, M Blood Cancer J Letter to the Editor Nature Publishing Group 2015-04 2015-04-10 /pmc/articles/PMC4450327/ /pubmed/25860291 http://dx.doi.org/10.1038/bcj.2015.27 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Dwojak, M Bobrowicz, M Bil, J Bojarczuk, K Pyrzynska, B Siernicka, M Malenda, A Lech-Maranda, E Tomczak, W Giannopoulos, K Golab, J Winiarska, M Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| title | Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| title_full | Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| title_fullStr | Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| title_full_unstemmed | Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| title_short | Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| title_sort | sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450327/ https://www.ncbi.nlm.nih.gov/pubmed/25860291 http://dx.doi.org/10.1038/bcj.2015.27 |
| work_keys_str_mv | AT dwojakm sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT bobrowiczm sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT bilj sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT bojarczukk sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT pyrzynskab sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT siernickam sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT malendaa sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT lechmarandae sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT tomczakw sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT giannopoulosk sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT golabj sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins AT winiarskam sorafenibimprovesrituximabandofatumumabefficacybydecreasingtheexpressionofcomplementregulatoryproteins |